Durect Corp (DRRX)
1.35
+0.04
(+3.05%)
USD |
NASDAQ |
Jul 02, 16:00
1.35
0.00 (0.00%)
After-Hours: 18:27
Durect Research and Development Expense (TTM): 24.88M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 24.88M |
| December 31, 2023 | 29.35M |
| September 30, 2023 | 33.69M |
| June 30, 2023 | 36.37M |
| March 31, 2023 | 37.24M |
| December 31, 2022 | 36.86M |
| September 30, 2022 | 35.32M |
| June 30, 2022 | 33.47M |
| March 31, 2022 | 32.08M |
| December 31, 2021 | 31.85M |
| September 30, 2021 | 30.12M |
| June 30, 2021 | 28.96M |
| March 31, 2021 | 28.10M |
| December 31, 2020 | 27.71M |
| September 30, 2020 | 29.91M |
| June 30, 2020 | 30.94M |
| March 31, 2020 | 30.98M |
| December 31, 2019 | 29.64M |
| September 30, 2019 | 26.15M |
| June 30, 2019 | 24.79M |
| March 31, 2019 | 24.31M |
| December 31, 2018 | 25.01M |
| September 30, 2018 | 26.22M |
| June 30, 2018 | 28.05M |
| March 31, 2018 | 31.01M |
| Date | Value |
|---|---|
| December 31, 2017 | 31.61M |
| September 30, 2017 | 33.00M |
| June 30, 2017 | 31.42M |
| March 31, 2017 | 30.20M |
| December 31, 2016 | 29.27M |
| September 30, 2016 | 27.94M |
| June 30, 2016 | 27.79M |
| March 31, 2016 | 25.58M |
| December 31, 2015 | 24.32M |
| September 30, 2015 | 23.07M |
| June 30, 2015 | 21.88M |
| March 31, 2015 | 22.33M |
| December 31, 2014 | 22.43M |
| September 30, 2014 | 21.87M |
| June 30, 2014 | 20.88M |
| March 31, 2014 | 19.62M |
| December 31, 2013 | 18.94M |
| September 30, 2013 | 19.00M |
| June 30, 2013 | 19.27M |
| March 31, 2013 | 19.42M |
| December 31, 2012 | 20.26M |
| September 30, 2012 | 22.37M |
| June 30, 2012 | 26.08M |
| March 31, 2012 | 29.81M |
| December 31, 2011 | 34.05M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
24.88M
Minimum
Mar 2024
37.24M
Maximum
Mar 2023
31.24M
Average
30.94M
Median
Jun 2020
Research and Development Expense (TTM) Benchmarks
| Harrow Inc | 8.067M |
| Stereotaxis Inc | 9.77M |
| Cara Therapeutics Inc | 106.14M |
| Voyager Therapeutics Inc | 100.70M |
| Journey Medical Corp | 13.39M |